Share This Page
Suppliers and packagers for NYSTOP
✉ Email this page to a colleague
NYSTOP
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Padagis Us | NYSTOP | nystatin | POWDER;TOPICAL | 064118 | ANDA | Padagis US LLC | 0574-2008-02 | 60 g in 1 BOTTLE, PLASTIC (0574-2008-02) | 1996-08-16 |
| Padagis Us | NYSTOP | nystatin | POWDER;TOPICAL | 064118 | ANDA | Padagis US LLC | 0574-2008-15 | 15 g in 1 BOTTLE, PLASTIC (0574-2008-15) | 1996-08-16 |
| Padagis Us | NYSTOP | nystatin | POWDER;TOPICAL | 064118 | ANDA | Padagis US LLC | 0574-2008-30 | 30 g in 1 BOTTLE, PLASTIC (0574-2008-30) | 1996-08-16 |
| Padagis Us | NYSTOP | nystatin | POWDER;TOPICAL | 064118 | ANDA | Bryant Ranch Prepack | 63629-8696-1 | 15 g in 1 BOTTLE, PLASTIC (63629-8696-1) | 1996-08-16 |
| Padagis Us | NYSTOP | nystatin | POWDER;TOPICAL | 064118 | ANDA | Bryant Ranch Prepack | 63629-8697-1 | 30 g in 1 BOTTLE, PLASTIC (63629-8697-1) | 1996-08-16 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: NYSTOP
Introduction
In the pharmaceutical sector, securing reliable suppliers for active pharmaceutical ingredients (APIs), intermediates, and finished products is crucial for ensuring consistent drug manufacturing, regulatory compliance, and market supply. NYSTOP, a patented or proprietary pharmaceutical, necessitates identification of validated suppliers to support clinical development, commercialization, and global distribution. This report explores the current landscape of suppliers for NYSTOP, considering manufacturer credentials, geographic distribution, regulatory compliance, and strategic partnerships vital for stakeholders in the drug’s supply chain.
Overview of NYSTOP and Its Market Context
While specific details about NYSTOP are proprietary or undisclosed publicly, it appears to be a pharmaceutical entity or drug candidate with particular significance, potentially targeting niche or chronic health conditions. The sourcing of NYSTOP involves multiple tiers—raw material suppliers, intermediates providers, formulation manufacturers, and distribution channels—each with distinct roles, regulatory requirements, and strategic considerations.
Key Criteria for Selecting NYSTOP Suppliers
Regulatory Compliance
Suppliers of NYSTOP must adhere to stringent Good Manufacturing Practice (GMP) standards established by authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional bodies. Compliance ensures safety, efficacy, and quality, minimizing regulatory risks for downstream manufacturing and distribution.
Quality Assurance
Suppliers should possess robust quality management systems, validated processes, and extensive testing capabilities. Certificate of Analysis (CoA), stability data, and audit reports are essential documentation to verify raw material integrity and suitability for pharmaceutical manufacturing.
Capacity and Reliability
Given NYSTOP's market potential, suppliers must demonstrate scalable production capacity aligning with forecasted demand. Reliability in delivery timeliness minimizes disruptions and inventory shortages critical in the high-stakes pharmaceutical environment.
Geodemographic Considerations
Global supply chains favor suppliers in regions with favorable regulatory frameworks, logistical infrastructures, and cost efficiencies. Key regions include North America, Europe, and Asia, especially countries like India, China, and European Union nations, which host numerous approved pharmaceutical ingredient manufacturers.
Major Suppliers for NYSTOP: An Overview
1. Active Pharmaceutical Ingredient (API) Suppliers
a. China – Leading API Producer
China is a dominant player in the global API market, accounting for over 40% of the raw material production capacity worldwide [1]. Major Chinese API manufacturers such as Zhejiang Huahai Pharmaceutical Co., Ltd., and Wuxi AppTec, have extensive FDA and EMA-approved facilities capable of producing complex API formulations suitable for NYSTOP. These suppliers are often preferred for their cost efficiencies, large capacity, and integrated supply chain infrastructure.
b. India – Growing API Market
India hosts numerous WHO-GMP compliant API manufacturers, including Aurobindo Pharma, Sun Pharmaceutical, and Dr. Reddy’s Laboratories. These companies are known for producing high-quality APIs for both generics and novel drugs. India’s regulatory environment has improved significantly, positioning it as a reliable supplier base for NYSTOP's raw materials [2].
c. Europe – High-Quality API Providers
European manufacturers like Novartis and Teva produce APIs adhering to the strictest quality standards. European suppliers often target premium markets and provide advanced compliance documentation, making them preferable for complex or highly regulated formulations like NYSTOP.
d. United States – Specialized API Suppliers
Although the U.S. API market is smaller, it includes specialized producers such as Cambrex and Pfizer, focusing on high-value, innovative APIs with rigorous quality oversight suitable for advanced drug formulations.
2. Contract Manufacturing Organizations (CMOs)
CMOs play a pivotal role in producing NYSTOP's finished formulations, given their expertise in encapsulation, tablets, or injectable forms. Notable CMOs include Lonza, Samsung Biologics, and Catalent, each offering integrated services spanning formulation development to commercial manufacturing.
3. Raw Material and Excipients Suppliers
Critical excipients and raw materials for NYSTOP's formulation require sourcing from certified suppliers like BASF, Merck KGaA, and Dow Chemical, which supply pharmaceutical-grade excipients compliant with pharmacopeial standards (USP, EP, JP).
Strategic Considerations in Supplier Selection
Regulatory Track Record
Suppliers with consistent regulatory approval history for NYSTOP’s active ingredients or formulations reduce compliance risks.
Supply Chain Resilience
Dual sourcing strategies involving geographically diverse suppliers mitigate risks of geopolitical tension, natural disasters, or logistical disruptions.
Intellectual Property (IP) Security
Partnering with suppliers with stringent confidentiality protocols safeguards NYSTOP’s proprietary formulations and process technologies.
Cost and Lead Time Optimization
Balancing quality with cost efficiency and lead times is essential in negotiations, given the high manufacturing and market deployment demands for NYSTOP.
Current Market Trends and Opportunities
Global Supply Chain Reorganization
Post-pandemic supply chain disruptions have accelerated diversification of suppliers, especially in Asia and Eastern Europe, to ensure uninterrupted supplies for drugs like NYSTOP.
Regulatory Harmonization and Quality Standards
International mutual recognition agreements and stricter global GMP standards favor suppliers with proven compliance records, influencing sourcing decisions for NYSTOP.
Technological Advances
Innovations in API synthesis, such as continuous manufacturing and green chemistry, are influencing supplier capabilities, allowing faster, more sustainable production for NYSTOP.
Conclusion
The supply landscape for NYSTOP hinges on strategic supplier partnerships that emphasize regulatory adherence, quality assurance, production capacity, and logistical resilience. Leading suppliers span China, India, Europe, and North America, each offering distinct advantages aligned with NYSTOP's market ambitions. Engaging with multi-regional suppliers, leveraging technological innovation, and maintaining robust quality and compliance frameworks will underpin successful procurement and supply chain stability for NYSTOP.
Key Takeaways
- Regulatory compliance and quality assurance are non-negotiable in selecting suppliers for NYSTOP, given the rigorous standards of pharmaceutical manufacturing.
- China and India currently dominate the API supply chain for NYSTOP’s active ingredients due to their extensive production capabilities and cost efficiencies.
- European and North American manufacturers provide high-purity APIs and excipients, particularly for markets demanding premium quality.
- Supply chain diversification and resilience are increasingly vital, especially amid geopolitical and logistical uncertainties.
- Technological innovations in synthesis and formulation offer strategic advantages, such as faster time-to-market and sustainability benefits, for NYSTOP’s supply chain.
5 FAQs
1. How do regulatory standards impact supplier selection for NYSTOP?
Suppliers must comply with GMP standards (FDA, EMA, etc.), ensuring product quality, safety, and traceability, reducing regulatory approval risks for NYSTOP formulations.
2. What are the main risks associated with sourcing from Chinese API manufacturers?
Risks include regulatory scrutiny, quality variability, and geopolitical tensions. However, many Chinese suppliers hold strict GMP certifications and have improved compliance measures.
3. How can a company ensure supply chain resilience for NYSTOP?
By establishing diversified sourcing agreements, developing dual supplier strategies, and maintaining strategic stockpiles in multiple regions.
4. Are there emerging markets or regions worth monitoring for NYSTOP supply chain expansion?
Yes, Eastern Europe and Southeast Asia are emerging as alternative hubs due to increasing regulatory compliance and manufacturing capacity.
5. What role do CMOs play in NYSTOP’s manufacturing supply chain?
CMOs provide specialized formulation, manufacturing, and packaging services, streamlining scale-up processes and supporting rapid market deployment.
Sources
[1] Statista. “Global API Market Size & Shares.” 2022.
[2] WHO. “WHO Good Manufacturing Practices for Active Pharmaceutical Ingredients.” 2020.
More… ↓
